TherapeuticsMD (TXMD) Amortization of Deferred Charges (2011 - 2026)

TherapeuticsMD's Amortization of Deferred Charges history runs 10 years deep, the most recent figure standing at $231000.0 for Q1 2026.

• Quarterly Amortization of Deferred Charges rose 50.0% year-over-year to $231000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $10.9 million (down 44.74% YoY) and the FY2025 annual result came in at $809000.0, up 4.93% from the prior year.
• Amortization of Deferred Charges was $231000.0 for Q1 2026 at TherapeuticsMD, up from $154000.0 in the prior quarter.
• Across five years, Amortization of Deferred Charges topped out at $9.0 million in Q1 2022 and bottomed at $154000.0 in Q1 2025.
• A 3-year average of $4.0 million and a median of $2.6 million in 2022 frame the typical range for Amortization of Deferred Charges.
• Annual changes were most pronounced in 2022 — Amortization of Deferred Charges soared 611.32% — and 2026, when it jumped 50.0%.
• TherapeuticsMD's Amortization of Deferred Charges stood at $2.6 million in 2022, then sank by 94.04% to $154000.0 in 2025, then soared by 50.0% to $231000.0 in 2026.
• Business Quant data shows TXMD's Amortization of Deferred Charges at $231000.0 in Q1 2026, $154000.0 in Q1 2025, and $2.6 million in Q3 2022.